Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 4/20 | 0.44 |
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658124 | 0.91 | THRB (0.45) | THRBTHRA | |
| SCHEMBL6660362 | 0.88 | THRA (0.58) | PPARGTHRBTHRAPLA2G7 | |
| SCHEMBL6659411 | 0.88 | POLB (0.47) | THRBTHRA | |
| SCHEMBL6658141 | 0.86 | THRA (0.47) | THRBTHRA | |
| SCHEMBL1642056 | 0.86 | HSD17B3 (0.44) | THRBTHRA | |
| SCHEMBL6660170 | 0.85 | THRB (0.43) | THRBTHRAALDH1A1 | |
| SCHEMBL6658703 | 0.83 | THRB (0.44) | THRBTHRA | |
| SCHEMBL6664797 | 0.82 | THRA (0.53) | THRBTHRA | |
| SCHEMBL6658109 | 0.80 | THRA (0.55) | THRBTHRA | |
| SCHEMBL1640543 | 0.80 | THRA (0.51) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| EP-1157001-B1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | disclosed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
| US-6326398-B1 | Oxamic acids and derivatives as thyroid receptor ligands | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| EP-1157001-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051971-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | PPARG 414/4885THRB 4/4885THRA 2/4885 |
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | PPARG 470/4885THRB 7/4885THRA 2/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | PPARG 235/4885THRB 4/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.